Effects of Di'ao Xinxuekang Capsule on major adverse cardiovascular events after percutaneous coronary intervention

To observe the effect of Di'ao Xinxuekang capsule on major adverse cardiovascular events (MACE) in patients with coronary heart disease after percutaneous coronary intervention (PCI). The clinical data of 60 patients with coronary heart disease who underwent PCI in Xinmi Traditional Chinese Medicine Hospital from January 2021 to January 2023 and were followed up for 1 year were retrospectively analyzed. According to whether they continued to take Di'ao Xinxuekang Capsules on the basis of conventional western medicine treatment after surgery, they were divided into an observation group (conventional treatment after surgery + Di'ao Xinxuekang Capsules) and a control group (conventional treatment after surgery). The changes in the primary outcome indicators (MACE incidence) and secondary outcome indicators (low-density lipoprotein cholesterol level, left ventricular ejection fraction) between the two groups were analyzed and compared. Thirty subjects who met the criteria were included in the observation group and the control group, respectively. In the observation group, there were 20 males and 10 females, with an age of (58.43±10.15) years, a course of coronary heart disease of (1.70±1.90) years, and the number of stents implanted was (1.20±0.55). In the control group, there were 21 males and 9 females, with an age of (62.27±8.36) years, a course of coronary heart disease of (1.80±0.76) years, and the number of stents implanted was (1.23±0.43). The incidence of MACE in the observation group was 16.67% (5/30), which was lower than 40.0% (12/30) in the control group (χ2 = 4.02, P =0.045). The low-density lipoprotein cholesterol level in the observation group was (1.57±0.76) mmol/L, which was lower than (2.22±0.91) mmol/L in the control group (t =-3.00, P =0.004). The left ventricular ejection fraction in the observation group was (60.27±4.84)%, which was higher than (57.37±5.86)% in the control group ( t =2.09, P =0.041). Di'ao Xinxuekang Capsule can reduce the incidence of MACE after PCI in patients with coronary heart disease and improve the cardiac function of patients.